NVO - Novo Nordisk A/S

NYSE - NYSE Delayed Price. Currency in USD
52.52
-0.16 (-0.30%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close52.68
Open52.63
Bid52.49 x 1000
Ask52.50 x 800
Day's Range52.17 - 52.65
52 Week Range41.59 - 53.55
Volume773,615
Avg. Volume1,429,123
Market Cap124.263B
Beta (3Y Monthly)0.62
PE Ratio (TTM)21.33
EPS (TTM)2.46
Earnings DateN/A
Forward Dividend & Yield1.25 (2.39%)
Ex-Dividend Date2019-03-22
1y Target Est57.90
Trade prices are not sourced from all markets
  • PFE vs. NVO: Which Stock Is the Better Value Option?
    Zacks

    PFE vs. NVO: Which Stock Is the Better Value Option?

    PFE vs. NVO: Which Stock Is the Better Value Option?

  • The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices
    Zacks

    The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices

    The Zacks Analyst Blog Highlights: Intel, Oracle, Novo Nordisk, ConocoPhillips and Advanced Micro Devices

  • Top Analyst Reports for Intel, Oracle & Novo Nordisk
    Zacks

    Top Analyst Reports for Intel, Oracle & Novo Nordisk

    Top Analyst Reports for Intel, Oracle & Novo Nordisk

  • The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
    Zacks

    The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

    The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

  • New Sanofi CEO Looks to Shake Things Up
    GuruFocus.com

    New Sanofi CEO Looks to Shake Things Up

    Paul Hudson is examining the organization from top to bottom with the goal of developing a strategy to put the company on the road to success Continue reading...

  • Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
    Zacks

    Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals

    FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.

  • Gilead-Galapagos Report Efficacy & Safety Results on RA Drug
    Zacks

    Gilead-Galapagos Report Efficacy & Safety Results on RA Drug

    Gilead (GILD) announces 52-week efficacy and safety results on experimental RA drug, filgotinib, from two late-stage studies.

  • bluebird Inks Genome Editing Research Deal With Novo Nordisk
    Zacks

    bluebird Inks Genome Editing Research Deal With Novo Nordisk

    bluebird (BLUE) signs a collaboration contract with Novo Nordisk to develop next-generation in vivo genome editing therapies for the treatment of genetic disorders including hemophilia.

  • Is Novo Nordisk A/S  (NVO) A Good Stock To Buy?
    Insider Monkey

    Is Novo Nordisk A/S (NVO) A Good Stock To Buy?

    Is Novo Nordisk A/S (NYSE:NVO) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]

  • 5 European Health Care Companies With High Business Quality
    GuruFocus.com

    5 European Health Care Companies With High Business Quality

    European markets offer opportunities as investors await US-China trade talks Continue reading...

  • Novo Nordisk Focuses on Pipeline Development Amid Competition
    Zacks

    Novo Nordisk Focuses on Pipeline Development Amid Competition

    Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.

  • Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
    Zacks

    Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion

    Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.

  • An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 25% Undervalued
    Simply Wall St.

    An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 25% Undervalued

    Does the October share price for Novo Nordisk A/S (CPH:NOVO B) reflect what it's really worth? Today, we will estimate...

  • 4 High-Quality US Stocks as Trade War Fears Are Rekindled
    GuruFocus.com

    4 High-Quality US Stocks as Trade War Fears Are Rekindled

    Top Berkshire holding Apple makes list Continue reading...

  • Benzinga

    Cool Chain Association Calls For Data Sharing

    Cool chain partners are changing their mindsets to join shippers and start-ups shaping the supply chain of the future, according to speakers at the recent Cool Chain Association's (CCA) pharma and biosciences conference in Paris. Conference delegates also heard that the air cargo industry could make a difference in final mile delivery that could save the lives of infants. The CCA, which hosts two regular events each year, one on pharma and one on perishables, brings together industry leaders from across the cool chain to network.

  • SNY or NVO: Which Is the Better Value Stock Right Now?
    Zacks

    SNY or NVO: Which Is the Better Value Stock Right Now?

    SNY vs. NVO: Which Stock Is the Better Value Option?

  • GuruFocus.com

    Foreign Firms Recognized as Hottest Biotechs

    For the first time since FierceBiotech issued its list, companies outside the US are included Continue reading...

  • Enanta's Stock Down Despite NASH Drug Meeting Goal in Study
    Zacks

    Enanta's Stock Down Despite NASH Drug Meeting Goal in Study

    Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours trading.

  • Moody's

    Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023

    China's pharmaceutical market will be an important source of growth for the entire global pharma industry over the next five years as regulatory reforms and improving healthcare coverage fuel the country's growing demand for innovative drugs, Moody's Investors Service said today in a new report. Companies with a major China presence already will most benefit thanks to their experience navigating the complex Chinese market and their established sales channels. While strong volume growth is expected for the growing number of drugs included on China's National Drug Reimbursement List, inclusion on the list often implies heavy discounting, potentially placing pressure on profit margins unless offset by volume growth.

  • Moody's

    Novo Nordisk A/S -- Moody's announces completion of a periodic review of ratings of Novo Nordisk A/S

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Novo Nordisk A/S and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • How Novo Nordisk Is Aiming To Take A Slice Of Lilly's Diabetes Market
    Investor's Business Daily

    How Novo Nordisk Is Aiming To Take A Slice Of Lilly's Diabetes Market

    Novo Nordisk's newest diabetes treatment, an oral drug called Rybelsus, won't immediately gouge another medicine from pharmaceutical company Eli Lilly. Both are GLP-1 receptor agonists.

  • Why this diabetes patient fears a no-deal Brexit
    Reuters Videos

    Why this diabetes patient fears a no-deal Brexit

    Her daily routine is a matter of life and death for Georgina. She is one of Britain's one million diabetics now facing the possibility of medical shortages if the UK plunges out of the European Union without a deal at the end of October. (SOUNDBITE) (English) LONDON RESIDENT AND DIABETES PATIENT, GEORGINA, SAYING: "I can't tell you how worried I am about that. It's life-threatening for me." Her fears have been exacerbated by the British government's own planning for a worst case scenario. The Yellowhammer document suggests the important Calais to Dover trade route could face months of disruption, and the pharmaceuticals industry is particularly vulnerable. That's because three quarters of the 37 million packs of drugs imported from Europe each month, come through the short straits route. Georgina is concerned that the medical supplies she depends on could dwindle. She tests her blood sugar levels four times a day to work out how much of an insulin boost she needs at meal times, in addition to a pump that gives her a low level dosage of insulin 24 hours a day. (SOUNDBITE) (English) LONDON RESIDENT AND DIABETES PATIENT, GEORGINA, SAYING: "I can live without the pump and I can live without all the bits and pieces that go with the pump but I cannot live without the blood testing strips because that's just as important, nearly as important, as having an adequate insulin supply. And the two really go so hand in hand, that's the one thing I don't think people realize." She may take some comfort from private sector preparations. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "At Novo Nordisk we've been preparing for the last three years, if not more than that, for the worst-case scenario." Pinder Sahota is the UK general manager of the world's biggest insulin maker, Novo Nordisk. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "So what we've done is we've increased our stock level from - a normal average of stock-holding is six weeks, we've increased that to 18 weeks." That's a warehouse capacity of 3.8 million packs of insulin. Piled up - they'd stand 12 times the height of London's Shard skyscraper. Novo Nordisk has also reserved spaces on alternate ferry routes and air freight if required while exploring other factors such as what to do in the event of fuel shortages. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "Whilst we can control what we can control, it's the uncertainties of how long will the delays be, that are factors outside our control. But we're doing everything we can to ensure that the patients can continue to get the medicines that they need." But the situation is increasing tensions between industry and the government - and not just around the intricacies of planning for a no-deal. Hugo Fry, UK managing director of France's Sanofi, also says that patients have to be prioritized. (SOUNDBITE) (English) MANAGING DIRECTOR OF SANOFI UK, HUGO FRY, SAYING: "Of course, we're starting to ask ourselves the question... although we're happy to do it, it is starting to weigh on our balance sheet, on our logistics, keeping all this additional stock in the country." And that leads to another frustration - that while the companies like Sanofi and Novo Nordisk dedicate huge resources to such preparation, they are having to spend less time on their normal job - bringing innovative drugs to market.